Do analysts prefer ZLAB or ZSQR?

Zai Lab presently has a consensus target price of $40.00, indicating a potential upside of 109.21%. Given Zai Lab's stronger consensus rating and higher probable upside, equities analysts clearly believe Zai Lab is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ZLAB or ZSQR?

In the previous week, Zai Lab had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 8 mentions for Zai Lab and 4 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.25 beat Zai Lab's score of -0.12 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GENB or ZSQR?

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Generate Biomedicines. Coeptis Therapeutics' average media sentiment score of 0.25 beat Generate Biomedicines' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ZSQR or HRMY?

Harmony Biosciences has a consensus price target of $41.44, suggesting a potential upside of 11.23%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Harmony Biosciences 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27

Does the media prefer ZSQR or HRMY?

In the previous week, Coeptis Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.75 beat Coeptis Therapeutics' score of 0.25 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ZSQR or OCUL?

Ocular Therapeutix has a consensus price target of $25.11, indicating a potential upside of 160.49%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79

Does the media prefer ZSQR or OCUL?

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 3 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.56 beat Coeptis Therapeutics' score of 0.25 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZSQR or STOK?

Stoke Therapeutics has a consensus price target of $41.83, suggesting a potential upside of 27.93%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Stoke Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73

Does the media prefer ZSQR or STOK?

In the previous week, Coeptis Therapeutics had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 1 mentions for Stoke Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.25 beat Stoke Therapeutics' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Coeptis Therapeutics (ZSQR) Competitors

$10.99 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

ZSQR vs. ZLAB, GENB, HRMY, OCUL, and STOK

Should you buy Coeptis Therapeutics stock or one of its competitors? MarketBeat compares Coeptis Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coeptis Therapeutics include Zai Lab (ZLAB), Generate Biomedicines (GENB), Harmony Biosciences (HRMY), Ocular Therapeutix (OCUL), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

How does Coeptis Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Coeptis Therapeutics (NASDAQ:ZSQR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Coeptis Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.71	-$175.54M	-$1.62	N/A
Coeptis Therapeutics	$1.36M	415.60	-$11.92M	-$2.52	N/A

Zai Lab has a net margin of -39.29% compared to Coeptis Therapeutics' net margin of -810.04%. Zai Lab's return on equity of -24.32% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zai Lab presently has a consensus target price of $40.00, indicating a potential upside of 109.21%. Given Zai Lab's stronger consensus rating and higher probable upside, equities analysts clearly believe Zai Lab is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zai Lab has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, Zai Lab had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 8 mentions for Zai Lab and 4 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.25 beat Zai Lab's score of -0.12 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zai Lab beats Coeptis Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Coeptis Therapeutics (NASDAQ:ZSQR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Coeptis Therapeutics has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A
Coeptis Therapeutics	$1.36M	415.60	-$11.92M	-$2.52	N/A

Generate Biomedicines currently has a consensus price target of $25.40, indicating a potential upside of 45.89%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe Generate Biomedicines is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Generate Biomedicines. Coeptis Therapeutics' average media sentiment score of 0.25 beat Generate Biomedicines' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Generate Biomedicines' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Generate Biomedicines beats Coeptis Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Harmony Biosciences?

Coeptis Therapeutics (NASDAQ:ZSQR) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Coeptis Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.75 beat Coeptis Therapeutics' score of 0.25 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harmony Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a consensus price target of $41.44, suggesting a potential upside of 11.23%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Harmony Biosciences has a net margin of 16.20% compared to Coeptis Therapeutics' net margin of -810.04%. Harmony Biosciences' return on equity of 17.19% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Harmony Biosciences	16.20%	17.19%	11.99%

Coeptis Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	415.60	-$11.92M	-$2.52	N/A
Harmony Biosciences	$868.45M	2.48	$158.69M	$2.48	15.02

Summary

Harmony Biosciences beats Coeptis Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Ocular Therapeutix?

Coeptis Therapeutics (NASDAQ:ZSQR) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Coeptis Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	415.60	-$11.92M	-$2.52	N/A
Ocular Therapeutix	$51.95M	40.63	-$265.94M	-$1.46	N/A

Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 3 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.56 beat Coeptis Therapeutics' score of 0.25 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a consensus price target of $25.11, indicating a potential upside of 160.49%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Ocular Therapeutix has a net margin of -558.24% compared to Coeptis Therapeutics' net margin of -810.04%. Ocular Therapeutix's return on equity of -64.28% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ocular Therapeutix beats Coeptis Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Stoke Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Stoke Therapeutics has higher revenue and earnings than Coeptis Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	415.60	-$11.92M	-$2.52	N/A
Stoke Therapeutics	$184.42M	11.04	-$6.89M	-$2.81	N/A

In the previous week, Coeptis Therapeutics had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 1 mentions for Stoke Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.25 beat Stoke Therapeutics' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stoke Therapeutics has a consensus price target of $41.83, suggesting a potential upside of 27.93%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Stoke Therapeutics has a net margin of -529.20% compared to Coeptis Therapeutics' net margin of -810.04%. Stoke Therapeutics' return on equity of -48.84% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Coeptis Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Stoke Therapeutics beats Coeptis Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$565.22M	$3.76B	$6.98B	$12.46B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-4.36	21.80	27.80	24.70
Price / Sales	415.60	326.25	535.80	98.72
Price / Cash	N/A	64.18	29.65	49.23
Price / Book	4.18	8.67	10.87	6.49
Net Income	-$11.92M	$23.68M	$3.57B	$336.25M
7 Day Performance	-5.83%	1.23%	1.14%	0.35%
1 Month Performance	8.60%	13.43%	6.07%	3.91%
1 Year Performance	44.23%	62.61%	33.30%	23.88%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.2168 of 5 stars	$10.99 flat	N/A	+44.2%	$565.22M	$1.36M	N/A	2	Gap Up
ZLAB Zai Lab	2.0961 of 5 stars	$19.15 +0.8%	$40.00 +108.9%	-47.5%	$2.17B	$460.16M	N/A	1,784
GENB Generate Biomedicines	2.0436 of 5 stars	$16.50 -2.2%	$25.40 +53.9%	N/A	$2.12B	$30.30M	N/A	312	Gap Down
HRMY Harmony Biosciences	4.5396 of 5 stars	$36.00 -1.1%	$41.44 +15.1%	+16.1%	$2.08B	$868.45M	14.52	200	Gap Down
OCUL Ocular Therapeutix	3.07 of 5 stars	$9.47 -3.6%	$25.11 +165.2%	+3.0%	$2.07B	$51.95M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. ZLAB, GENB, HRMY, OCUL, and STOK

How does Coeptis Therapeutics compare to Zai Lab?

Summary

How does Coeptis Therapeutics compare to Generate Biomedicines?

Summary

How does Coeptis Therapeutics compare to Harmony Biosciences?

Summary

How does Coeptis Therapeutics compare to Ocular Therapeutix?

Summary

How does Coeptis Therapeutics compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. ZLAB, GENB, HRMY, OCUL, and STOK

How does Coeptis Therapeutics compare to Zai Lab?

Which has stronger earnings & valuation, ZLAB or ZSQR?

Is ZLAB or ZSQR more profitable?

Do insiders and institutionals believe in ZLAB or ZSQR?

Do analysts prefer ZLAB or ZSQR?

Which has more risk & volatility, ZLAB or ZSQR?

Does the media refer more to ZLAB or ZSQR?

Summary

How does Coeptis Therapeutics compare to Generate Biomedicines?

Do institutionals and insiders believe in GENB or ZSQR?

Which has higher valuation and earnings, GENB or ZSQR?

Do analysts prefer GENB or ZSQR?

Does the media refer more to GENB or ZSQR?

Is GENB or ZSQR more profitable?

Summary

How does Coeptis Therapeutics compare to Harmony Biosciences?

Do insiders & institutionals hold more shares of ZSQR or HRMY?

Does the media prefer ZSQR or HRMY?

Do analysts rate ZSQR or HRMY?

Is ZSQR or HRMY more profitable?

Which has more volatility & risk, ZSQR or HRMY?

Which has preferable valuation & earnings, ZSQR or HRMY?

Summary

How does Coeptis Therapeutics compare to Ocular Therapeutix?

Which has stronger earnings and valuation, ZSQR or OCUL?

Which has more volatility & risk, ZSQR or OCUL?

Does the media prefer ZSQR or OCUL?

Do analysts recommend ZSQR or OCUL?

Is ZSQR or OCUL more profitable?

Do institutionals & insiders believe in ZSQR or OCUL?

Summary

How does Coeptis Therapeutics compare to Stoke Therapeutics?

Which has better earnings & valuation, ZSQR or STOK?

Does the media prefer ZSQR or STOK?

Do analysts rate ZSQR or STOK?

Is ZSQR or STOK more profitable?

Which has more risk and volatility, ZSQR or STOK?

Do institutionals and insiders hold more shares of ZSQR or STOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools